<< Read Full Article
<< Read Full Article
Odds, Analysts Against Human Genome's Lupus Drug
- Loading Comments...
Perhaps the biotech understatement of the year: Analysts are hating Human Genome Sciences(HGSI Quote) ahead of the company's release of results from a key lupus drug study next week.
The sell-side community tends to be an optimistic lot, which is why the near-universal negativity directed at Human Genome's drug Benlysta (formerly lymphostat-B) by almost every analyst covering the company cuts against the grain.
Human Genome will be releasing results from the Benlysta phase III study in lupus patients before the opening bell on Monday, July 20. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,328.89 | 1,102.47 | 2,211.69 | 35.46 |
Oil *
73.88
|
|
UP
20.63
|
UP
6.40
|
UP
31.64
|
UP
0.59
|
10 Yr
3.55%
SPDR Gold
108.95
|
|
+0.20%
|
+0.58%
|
+1.45%
|
+1.69%
|
Data delayed 20 minutes |
Connect with TheStreet